Pharmacology Quiz: Ibd Medications
20 questions · exam conditions
0:00
Ibd MedicationsQuestion 1 of 20

A patient with ulcerative colitis who has a history of a hypersensitivity reaction to sulfapyridine is switched to olsalazine. While their colitis symptoms improve, they develop significant, persistent watery diarrhea. This adverse effect is most directly caused by which mechanism?

An IgE-mediated allergic reaction to the azo-bond linkage in the olsalazine molecule.
An osmotic effect caused by the unabsorbed carrier molecule after mesalamine is cleaved.
Malabsorption of bile acids secondary to drug-induced inflammation in the terminal ileum.
A direct effect on colonic enterocytes, leading to increased chloride and fluid secretion.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Ibd Medications

Practice Ibd Medications in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Ibd Medications, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with ulcerative colitis who has a history of a hypersensitivity reaction to sulfapyridine is switched to olsalazine. While their colitis symptoms improve, they develop significant, persistent watery diarrhea. This adverse effect is most directly caused by which mechanism?

  1. An IgE-mediated allergic reaction to the azo-bond linkage in the olsalazine molecule.
  2. An osmotic effect caused by the unabsorbed carrier molecule after mesalamine is cleaved.
  3. Malabsorption of bile acids secondary to drug-induced inflammation in the terminal ileum.
  4. A direct effect on colonic enterocytes, leading to increased chloride and fluid secretion. (correct answer)
Explanation: When you encounter questions about inflammatory bowel disease medications causing new GI symptoms, focus on the specific mechanisms of action and known side effect profiles of each drug class. Olsalazine belongs to the mesalamine (5-ASA) family of anti-inflammatory drugs used for ulcerative colitis. Unlike sulfasalazine, olsalazine consists of two mesalamine molecules linked by an azo bond, with no sulfapyridine carrier. When colonic bacteria cleave this bond, both molecules become active mesalamine. The persistent watery diarrhea described here results from mesalamine's direct effect on colonic enterocytes, where it increases chloride and fluid secretion into the bowel lumen. This secretory diarrhea is a well-recognized dose-dependent side effect of olsalazine, occurring in up to 17% of patients. Answer A is incorrect because the patient's sulfapyridine allergy doesn't involve azo-bond hypersensitivity, and this diarrhea isn't IgE-mediated. Answer B misunderstands olsalazine's structure—there's no unabsorbed carrier molecule since both cleaved components are active mesalamine, not osmotically active waste products. Answer C describes a different pathophysiology entirely; olsalazine doesn't cause terminal ileum inflammation or bile acid malabsorption. The key study point: distinguish between different types of drug-induced diarrhea. Osmotic diarrhea (from unabsorbed substances), secretory diarrhea (from altered electrolyte transport), and inflammatory diarrhea (from mucosal damage) have different mechanisms. Olsalazine's diarrhea is secretory, caused by mesalamine's direct cellular effects on chloride channels.

Question 2

A 30-year-old patient with fistulizing Crohn's disease is a candidate for infliximab therapy. Due to the drug's mechanism of action, which of the following screening evaluations is essential prior to initiating treatment to prevent a potentially life-threatening opportunistic infection?

  1. A chest radiograph and an interferon-gamma release assay (IGRA). (correct answer)
  2. A complete blood count with differential to establish a leukocyte baseline.
  3. Serum antibody testing for previous exposure to Epstein-Barr virus (EBV).
  4. A comprehensive metabolic panel to assess renal and hepatic function.
Explanation: The correct answer is A. TNF-alpha is a critical cytokine for granuloma formation and containment of intracellular pathogens, most notably Mycobacterium tuberculosis. Inhibition of TNF-alpha with agents like infliximab can lead to the reactivation of latent tuberculosis (TB). Therefore, screening for latent TB with a chest X-ray and either a tuberculin skin test or an IGRA is mandatory before starting therapy. (B) and (D) are important baseline tests for monitoring but do not screen for the specific risk of TB reactivation. (C) is relevant for post-transplant lymphoproliferative disorder risk with thiopurines, but not a primary screening concern for anti-TNF agents.

Question 3

A 25-year-old patient with moderate ulcerative colitis, previously maintained on high-dose oral mesalamine, presents with a significant flare. The patient is successfully treated with a tapering course of oral prednisone. To maintain remission and facilitate steroid withdrawal, which of the following represents the most appropriate modification to the patient's long-term therapeutic plan?

  1. Switch from oral mesalamine to sulfasalazine due to its slightly superior efficacy in moderate disease.
  2. Plan for long-term, low-dose (5 mg/day) prednisone therapy as a maintenance strategy.
  3. Continue the high-dose oral mesalamine as the sole maintenance therapy after the prednisone taper is complete.
  4. Add a biologic agent, such as adalimumab or vedolizumab, to the ongoing mesalamine regimen. (correct answer)
Explanation: When managing inflammatory bowel disease like ulcerative colitis, you need to recognize escalation patterns and appropriate therapeutic stepping. This patient's clinical course signals inadequate disease control despite maximum medical therapy with mesalamine, requiring treatment intensification. The correct approach is D) Add a biologic agent because this patient has demonstrated steroid-dependent disease. When high-dose mesalamine fails to maintain remission and steroids are needed for flare control, current guidelines recommend advancing to biologics like adalimumab (anti-TNF) or vedolizumab (anti-integrin). These agents provide superior long-term remission rates and allow successful steroid withdrawal while working synergistically with ongoing mesalamine. A) Switching to sulfasalazine represents lateral movement rather than escalation. While sulfasalazine has marginal efficacy advantages over mesalamine in some studies, the difference is minimal and doesn't address the fundamental issue of inadequate disease control requiring steroids. B) Long-term low-dose prednisone violates a cardinal rule in IBD management. Chronic steroid use, even at 5mg daily, carries significant risks including osteoporosis, diabetes, and adrenal suppression, while providing inferior remission maintenance compared to biologics. C) Continuing mesalamine alone ignores the treatment failure that necessitated steroid rescue. This approach virtually guarantees future flares and repeated steroid exposure. Key strategy: In IBD pharmacology questions, remember the treatment pyramid concept. When patients require steroids for disease control despite optimal conventional therapy, it's time to escalate to immunomodulators or biologics, not maintain inadequate regimens or accept steroid dependence.

Question 4

The therapeutic effect of adalimumab in Crohn's disease is initiated by its high-affinity binding to soluble and transmembrane TNF-alpha. Which of the following downstream cellular events is a direct consequence of this binding and contributes most significantly to the reduction of mucosal inflammation?

  1. Inhibition of T-cell apoptosis, leading to a reduction in the population of autoreactive immune cells.
  2. Increased production of matrix metalloproteinases by fibroblasts, promoting tissue remodeling and rapid ulcer healing.
  3. Upregulation of regulatory T-cell function, promoting the secretion of the anti-inflammatory cytokine IL-10.
  4. Prevention of TNF-alpha from binding to its receptor, which downregulates NF-κB-mediated transcription of pro-inflammatory genes. (correct answer)
Explanation: When you encounter questions about monoclonal antibody therapeutics like adalimumab, focus on the direct mechanism of action rather than downstream secondary effects. These drugs work by physically blocking their target molecules. Adalimumab is a monoclonal antibody that binds directly to TNF-alpha, preventing this pro-inflammatory cytokine from reaching its cellular receptors. When TNF-alpha cannot bind to TNF receptors on cell surfaces, it cannot activate the NF-κB signaling pathway inside those cells. NF-κB is a master transcription factor that turns on genes for inflammatory mediators like IL-1, IL-6, and additional TNF-alpha. By blocking this cascade at its origin, adalimumab reduces the production of multiple inflammatory molecules that drive Crohn's disease pathology. This makes option D correct. Option A is backwards - adalimumab actually promotes apoptosis of activated immune cells, not inhibition. Option B describes a secondary healing response that occurs much later and isn't the primary anti-inflammatory mechanism. Option C mentions regulatory T-cells and IL-10, which are involved in immune regulation but aren't the direct result of TNF-alpha blockade. The key distinction here is between direct versus indirect effects. While adalimumab treatment may eventually lead to tissue remodeling, T-cell changes, and altered cytokine profiles, these are downstream consequences. The immediate therapeutic effect comes from physically preventing TNF-alpha from activating its inflammatory signaling pathways. Remember: monoclonal antibodies work by binding and neutralizing their targets, not by directly activating beneficial pathways. Focus on what gets blocked, not what gets enhanced.

Question 5

A patient with ulcerative colitis who initially responded well to infliximab maintenance therapy now presents with a recurrence of symptoms after 8 months. A therapeutic drug monitoring test reveals a very low trough concentration of infliximab and high titers of anti-infliximab antibodies. This finding is most consistent with which phenomenon?

  1. Mechanistic failure, where the disease is now driven by a non-TNF-alpha pathway.
  2. Non-adherence to the prescribed infusion schedule by the patient.
  3. Immunogenicity, leading to antibody-mediated accelerated clearance of the drug. (correct answer)
  4. A catabolic state due to severe inflammation, causing non-specific protein wasting.
Explanation: The correct answer is C. The combination of low drug levels and high anti-drug antibody (ADA) levels is the classic laboratory finding for secondary loss of response due to immunogenicity. The patient's immune system has developed antibodies against the infliximab molecule. These ADAs bind to infliximab, forming immune complexes that are rapidly cleared from circulation, leading to subtherapeutic drug levels and a return of symptoms. (A) would be suspected if drug levels were therapeutic but the patient was still symptomatic. (B) is possible but the presence of high ADAs points specifically to an immune mechanism. (D) might lead to low drug levels but would not explain the high ADA titers.

Question 6

A 55-year-old patient with Crohn's disease has required multiple, prolonged courses of prednisone over the past three years. A recent DEXA scan reveals a T-score of -2.8 in the lumbar spine, consistent with osteoporosis. This finding is a direct indication for which fundamental change in the patient's IBD management strategy?

  1. Increasing the patient's oral calcium and vitamin D supplementation dose while continuing prednisone as needed.
  2. Switching from prednisone to an equivalent anti-inflammatory dose of methylprednisolone to reduce bone effects.
  3. Aggressively pursuing a treatment strategy aimed at achieving steroid-free remission with a biologic or immunomodulator. (correct answer)
  4. Initiating bisphosphonate therapy but maintaining the current approach of using prednisone for flares.
Explanation: The correct answer is C. The development of a significant complication of corticosteroid therapy, such as osteoporosis, mandates a change in strategy to eliminate the offending agent. The primary goal becomes achieving and maintaining remission without the use of steroids. This is typically accomplished by initiating or optimizing therapy with steroid-sparing agents like biologics (e.g., anti-TNFs) or immunomodulators. (A) and (D) describe adjunctive treatments for osteoporosis but fail to address the root cause, which is the repeated steroid exposure. (B) is incorrect because methylprednisolone is another systemic corticosteroid with a similar risk profile for bone density loss.

Question 7

A patient with Crohn's disease is receiving their first infusion of infliximab. Twenty minutes into the infusion, they develop pruritus, urticaria, and a sensation of throat tightness. The infusion is immediately stopped. What is the most appropriate initial pharmacological intervention?

  1. Administer intravenous epinephrine and prepare for intubation.
  2. Administer oral acetaminophen and restart the infusion at half the original rate.
  3. Administer intravenous diphenhydramine and a corticosteroid like methylprednisolone. (correct answer)
  4. Administer intravenous ondansetron and a normal saline bolus.
Explanation: The correct answer is C. The patient is experiencing an acute infusion reaction, which is likely an IgE-mediated or non-IgE-mediated hypersensitivity reaction. The standard management for a moderate reaction (urticaria, throat tightness without stridor or severe hypotension) is to stop the infusion and administer intravenous antihistamines (like diphenhydramine) and corticosteroids to block the inflammatory cascade. (A) is reserved for anaphylaxis, which is a more severe reaction involving hemodynamic collapse or severe respiratory distress. (B) is incorrect; premedication with acetaminophen is for preventing non-allergic reactions, and restarting the infusion would be contraindicated until the reaction is controlled. (D) addresses nausea and dehydration, not the underlying hypersensitivity mechanism.

Question 8

A patient with ulcerative colitis involving the transverse colon is treated with an oral mesalamine formulation that uses a pH-sensitive Eudragit-S coating, designed to dissolve at a pH greater than 7.0. The patient is concurrently started on a high dose of esomeprazole for severe GERD. What is the most likely consequence of this drug combination on the patient's IBD therapy?

  1. Increased systemic absorption of mesalamine, leading to a higher risk of dose-dependent nephrotoxicity.
  2. Premature dissolution of the tablet's coating in the upper GI tract, reducing drug delivery to the colon. (correct answer)
  3. Delayed dissolution of the coating until the distal colon, leading to undertreatment of the transverse colon.
  4. A synergistic anti-inflammatory effect due to the combined mucosal-protective actions of both drugs.
Explanation: The correct answer is B. Proton pump inhibitors like esomeprazole significantly increase gastric pH. The Eudragit-S coating on this specific mesalamine formulation is designed to dissolve at a pH > 7.0, which is normally reached in the terminal ileum and colon. By raising the pH of the stomach and small intestine, esomeprazole can cause the coating to dissolve prematurely, releasing the mesalamine in the upper GI tract where it is not needed and reducing the amount that reaches the target site in the transverse colon, thereby decreasing efficacy. (A) is incorrect as premature release leads to less, not more, effective absorption for colonic action. (C) is incorrect; higher pH in the upper GI tract would cause earlier, not later, dissolution. (D) is incorrect as there is no known synergistic anti-inflammatory effect.

Question 9

A patient with a severe ulcerative colitis flare achieves significant symptomatic improvement after 2 weeks of high-dose (40 mg/day) oral prednisone. What is the most critical subsequent step in the management plan to ensure safe and effective long-term disease control?

  1. Continue the 40 mg/day dose of prednisone for at least 6 months to solidify remission and prevent relapse.
  2. Initiate a gradual dose taper of prednisone while concurrently starting a steroid-sparing maintenance agent. (correct answer)
  3. Stop the prednisone abruptly once symptoms resolve and monitor the patient for any signs of relapse.
  4. Switch the patient from oral prednisone to an equivalent anti-inflammatory dose of oral budesonide for maintenance.
Explanation: The correct answer is B. Corticosteroids are highly effective for inducing remission in IBD but are not suitable for long-term maintenance due to significant side effects. The standard of care is to use them for the shortest duration possible. Once remission is induced, the steroid dose must be tapered gradually to avoid adrenal insufficiency and disease flare. Concurrently, a steroid-sparing agent (such as a biologic or immunomodulator) should be initiated to maintain remission long-term. (A) is incorrect due to the high risk of steroid toxicity. (C) is incorrect because abrupt cessation can cause both a disease flare and adrenal crisis. (D) is incorrect as budesonide is also a corticosteroid and not intended for long-term maintenance therapy.

Question 10

A 34-year-old patient diagnosed with ulcerative proctosigmoiditis has persistent symptoms despite appropriate use of mesalamine suppositories. Which of the following is the most logical adjustment to the patient's 5-ASA therapy to ensure adequate drug delivery to the entire affected area?

  1. Switch to a pH-dependent release oral mesalamine formulation to achieve higher systemic levels.
  2. Add a mesalamine enema formulation to be used at bedtime in addition to the suppositories. (correct answer)
  3. Switch to an equivalent daily dose of oral sulfasalazine as it provides better distal colonic delivery.
  4. Increase the frequency of mesalamine suppository administration from twice to four times daily.
Explanation: The correct answer is B. Ulcerative proctosigmoiditis involves the rectum and sigmoid colon. Mesalamine suppositories effectively treat the rectum (typically 10-15 cm), but may not reach the sigmoid colon. A mesalamine enema can deliver the active drug more proximally to the sigmoid colon. Combining these or switching to an enema is the appropriate step. (A) is incorrect because oral formulations may not achieve sufficiently high topical concentrations in the distal colon compared to rectal therapy. (C) is incorrect because while sulfasalazine reaches the colon, rectal formulations provide more targeted, high-concentration delivery for distal disease. (D) is incorrect because increasing the suppository frequency will not extend its reach into the sigmoid colon.

Question 11

A 45-year-old male with ulcerative colitis, who has been stable on sulfasalazine for several years, presents with fatigue and dyspnea on exertion. Laboratory tests reveal a hemoglobin of 9.5 g/dL and a mean corpuscular volume (MCV) of 108 fL. This complication is most likely related to sulfasalazine's interference with the absorption of which substance?

  1. Iron
  2. Vitamin B12
  3. Folic acid (correct answer)
  4. Pyridoxine (Vitamin B6)
Explanation: The correct answer is C. The patient's lab results are consistent with macrocytic anemia. Sulfasalazine, specifically its sulfapyridine moiety, is known to be a competitive inhibitor of folate absorption and metabolism. This interference can lead to folic acid deficiency and subsequent macrocytic anemia. (A) is incorrect because iron deficiency leads to microcytic anemia (low MCV). (B) is incorrect because while B12 deficiency causes macrocytic anemia, it is not a common complication of sulfasalazine; it's more associated with Crohn's disease involving the terminal ileum. (D) is incorrect because pyridoxine deficiency is not the primary cause of this type of anemia.

Question 12

Balsalazide is a 5-ASA prodrug designed for targeted colonic delivery. Its mechanism to achieve this targeting differs significantly from that of a mesalamine tablet with an enteric, pH-sensitive coating. Which statement accurately describes the activation of balsalazide?

  1. Balsalazide is absorbed in the jejunum, undergoes hepatic conjugation, and is then secreted via bile into the colon for activation.
  2. Balsalazide is an inert molecule that passes through the upper GI tract unchanged until its azo bond is cleaved by bacterial azoreductases in the colon. (correct answer)
  3. Balsalazide is encapsulated in a special resin that only dissolves in the presence of short-chain fatty acids, which are abundant in the colon.
  4. Balsalazide requires a co-administered activating enzyme tablet, which is taken two hours after the prodrug to ensure colonic release.
Explanation: The correct answer is B. Balsalazide, along with sulfasalazine and olsalazine, is an azo-compound prodrug. It consists of a 5-ASA molecule linked by an azo bond (–N=N–) to an inert carrier molecule. This bond protects the 5-ASA from absorption or degradation in the stomach and small intestine. Upon reaching the colon, resident bacteria produce azoreductase enzymes that cleave the azo bond, releasing the active 5-ASA directly at the site of inflammation. The mechanisms described in (A), (C), and (D) are not how balsalazide functions.

Question 13

5-ASA agents like mesalamine are a cornerstone of maintenance therapy for mild-to-moderate ulcerative colitis but are not recommended as monotherapy for maintaining remission in Crohn's disease. Which of the following statements provides the most accurate rationale for this difference in efficacy?

  1. The inflammatory cascade in Crohn's disease is primarily transmural, making it less responsive to a topically acting agent like mesalamine. (correct answer)
  2. 5-ASA agents are rapidly and completely absorbed in the proximal small bowel, preventing delivery to common sites of Crohn's disease.
  3. The majority of 5-ASA formulations are inactivated by the acidic environment created by granulomas in Crohn's disease.
  4. Patients with Crohn's disease have a genetic polymorphism that leads to rapid metabolism of 5-ASA compounds.
Explanation: The correct answer is A. The primary mechanism of 5-ASA is thought to be a topical anti-inflammatory effect on the gut mucosa. In ulcerative colitis, inflammation is confined to the mucosal layer, allowing 5-ASA to be effective. In Crohn's disease, the inflammation is transmural, meaning it extends through the entire thickness of the bowel wall. This deep inflammation is less accessible and responsive to a topically acting agent. (B) is incorrect; various formulations are designed specifically to deliver mesalamine to the distal small bowel and colon. (C) and (D) are not established mechanisms for the lack of efficacy.

Question 14

A 28-year-old patient is diagnosed with a moderate flare of Crohn's disease localized to the terminal ileum and ascending colon. Which corticosteroid is the most appropriate choice for inducing remission while minimizing systemic adverse effects in this specific clinical scenario?

  1. Oral prednisone, because its high systemic bioavailability ensures adequate treatment of transmural inflammation.
  2. Intravenous hydrocortisone, because it bypasses potential issues with oral absorption during an acute flare.
  3. Oral controlled-release budesonide, due to its targeted release in the ileum and high first-pass metabolism. (correct answer)
  4. Oral dexamethasone, because its long half-life provides sustained 24-hour suppression of inflammation.
Explanation: The correct answer is C. Controlled-release budesonide is specifically designed to release the drug in the terminal ileum and proximal colon, making it ideal for Crohn's disease at this location. Furthermore, budesonide undergoes extensive (~90%) first-pass metabolism in the liver, which significantly reduces its systemic bioavailability and, consequently, the risk of systemic corticosteroid side effects compared to prednisone. (A), (B), and (D) all describe systemically acting corticosteroids which, while effective, would expose the patient to a much higher burden of systemic side effects than the more targeted budesonide.

Question 15

The therapeutic effect of adalimumab in Crohn's disease is initiated by its high-affinity binding to soluble and transmembrane TNF-alpha. Which of the following downstream cellular events is a direct consequence of this binding and contributes most significantly to the reduction of mucosal inflammation?

  1. Inhibition of T-cell apoptosis, leading to a reduction in the population of autoreactive immune cells.
  2. Increased production of matrix metalloproteinases by fibroblasts, promoting tissue remodeling and rapid ulcer healing.
  3. Upregulation of regulatory T-cell function, promoting the secretion of the anti-inflammatory cytokine IL-10.
  4. Prevention of TNF-alpha from binding to its receptor, which downregulates NF-κB-mediated transcription of pro-inflammatory genes. (correct answer)
Explanation: When you encounter questions about monoclonal antibody therapeutics like adalimumab, focus on the direct mechanism of action rather than downstream secondary effects. These drugs work by physically blocking their target molecules. Adalimumab is a monoclonal antibody that binds directly to TNF-alpha, preventing this pro-inflammatory cytokine from reaching its cellular receptors. When TNF-alpha cannot bind to TNF receptors on cell surfaces, it cannot activate the NF-κB signaling pathway inside those cells. NF-κB is a master transcription factor that turns on genes for inflammatory mediators like IL-1, IL-6, and additional TNF-alpha. By blocking this cascade at its origin, adalimumab reduces the production of multiple inflammatory molecules that drive Crohn's disease pathology. This makes option D correct. Option A is backwards - adalimumab actually promotes apoptosis of activated immune cells, not inhibition. Option B describes a secondary healing response that occurs much later and isn't the primary anti-inflammatory mechanism. Option C mentions regulatory T-cells and IL-10, which are involved in immune regulation but aren't the direct result of TNF-alpha blockade. The key distinction here is between direct versus indirect effects. While adalimumab treatment may eventually lead to tissue remodeling, T-cell changes, and altered cytokine profiles, these are downstream consequences. The immediate therapeutic effect comes from physically preventing TNF-alpha from activating its inflammatory signaling pathways. Remember: monoclonal antibodies work by binding and neutralizing their targets, not by directly activating beneficial pathways. Focus on what gets blocked, not what gets enhanced.

Question 16

A patient with ulcerative colitis involving the transverse colon is treated with an oral mesalamine formulation that uses a pH-sensitive Eudragit-S coating, designed to dissolve at a pH greater than 7.0. The patient is concurrently started on a high dose of esomeprazole for severe GERD. What is the most likely consequence of this drug combination on the patient's IBD therapy?

  1. Increased systemic absorption of mesalamine, leading to a higher risk of dose-dependent nephrotoxicity.
  2. Premature dissolution of the tablet's coating in the upper GI tract, reducing drug delivery to the colon. (correct answer)
  3. Delayed dissolution of the coating until the distal colon, leading to undertreatment of the transverse colon.
  4. A synergistic anti-inflammatory effect due to the combined mucosal-protective actions of both drugs.
Explanation: The correct answer is B. Proton pump inhibitors like esomeprazole significantly increase gastric pH. The Eudragit-S coating on this specific mesalamine formulation is designed to dissolve at a pH > 7.0, which is normally reached in the terminal ileum and colon. By raising the pH of the stomach and small intestine, esomeprazole can cause the coating to dissolve prematurely, releasing the mesalamine in the upper GI tract where it is not needed and reducing the amount that reaches the target site in the transverse colon, thereby decreasing efficacy. (A) is incorrect as premature release leads to less, not more, effective absorption for colonic action. (C) is incorrect; higher pH in the upper GI tract would cause earlier, not later, dissolution. (D) is incorrect as there is no known synergistic anti-inflammatory effect.

Question 17

A 45-year-old male with ulcerative colitis, who has been stable on sulfasalazine for several years, presents with fatigue and dyspnea on exertion. Laboratory tests reveal a hemoglobin of 9.5 g/dL and a mean corpuscular volume (MCV) of 108 fL. This complication is most likely related to sulfasalazine's interference with the absorption of which substance?

  1. Iron
  2. Vitamin B12
  3. Folic acid (correct answer)
  4. Pyridoxine (Vitamin B6)
Explanation: The correct answer is C. The patient's lab results are consistent with macrocytic anemia. Sulfasalazine, specifically its sulfapyridine moiety, is known to be a competitive inhibitor of folate absorption and metabolism. This interference can lead to folic acid deficiency and subsequent macrocytic anemia. (A) is incorrect because iron deficiency leads to microcytic anemia (low MCV). (B) is incorrect because while B12 deficiency causes macrocytic anemia, it is not a common complication of sulfasalazine; it's more associated with Crohn's disease involving the terminal ileum. (D) is incorrect because pyridoxine deficiency is not the primary cause of this type of anemia.

Question 18

A patient with a severe ulcerative colitis flare achieves significant symptomatic improvement after 2 weeks of high-dose (40 mg/day) oral prednisone. What is the most critical subsequent step in the management plan to ensure safe and effective long-term disease control?

  1. Continue the 40 mg/day dose of prednisone for at least 6 months to solidify remission and prevent relapse.
  2. Initiate a gradual dose taper of prednisone while concurrently starting a steroid-sparing maintenance agent. (correct answer)
  3. Stop the prednisone abruptly once symptoms resolve and monitor the patient for any signs of relapse.
  4. Switch the patient from oral prednisone to an equivalent anti-inflammatory dose of oral budesonide for maintenance.
Explanation: The correct answer is B. Corticosteroids are highly effective for inducing remission in IBD but are not suitable for long-term maintenance due to significant side effects. The standard of care is to use them for the shortest duration possible. Once remission is induced, the steroid dose must be tapered gradually to avoid adrenal insufficiency and disease flare. Concurrently, a steroid-sparing agent (such as a biologic or immunomodulator) should be initiated to maintain remission long-term. (A) is incorrect due to the high risk of steroid toxicity. (C) is incorrect because abrupt cessation can cause both a disease flare and adrenal crisis. (D) is incorrect as budesonide is also a corticosteroid and not intended for long-term maintenance therapy.

Question 19

A 55-year-old patient with Crohn's disease has required multiple, prolonged courses of prednisone over the past three years. A recent DEXA scan reveals a T-score of -2.8 in the lumbar spine, consistent with osteoporosis. This finding is a direct indication for which fundamental change in the patient's IBD management strategy?

  1. Increasing the patient's oral calcium and vitamin D supplementation dose while continuing prednisone as needed.
  2. Switching from prednisone to an equivalent anti-inflammatory dose of methylprednisolone to reduce bone effects.
  3. Aggressively pursuing a treatment strategy aimed at achieving steroid-free remission with a biologic or immunomodulator. (correct answer)
  4. Initiating bisphosphonate therapy but maintaining the current approach of using prednisone for flares.
Explanation: The correct answer is C. The development of a significant complication of corticosteroid therapy, such as osteoporosis, mandates a change in strategy to eliminate the offending agent. The primary goal becomes achieving and maintaining remission without the use of steroids. This is typically accomplished by initiating or optimizing therapy with steroid-sparing agents like biologics (e.g., anti-TNFs) or immunomodulators. (A) and (D) describe adjunctive treatments for osteoporosis but fail to address the root cause, which is the repeated steroid exposure. (B) is incorrect because methylprednisolone is another systemic corticosteroid with a similar risk profile for bone density loss.

Question 20

A patient with Crohn's disease is receiving their first infusion of infliximab. Twenty minutes into the infusion, they develop pruritus, urticaria, and a sensation of throat tightness. The infusion is immediately stopped. What is the most appropriate initial pharmacological intervention?

  1. Administer intravenous epinephrine and prepare for intubation.
  2. Administer oral acetaminophen and restart the infusion at half the original rate.
  3. Administer intravenous diphenhydramine and a corticosteroid like methylprednisolone. (correct answer)
  4. Administer intravenous ondansetron and a normal saline bolus.
Explanation: The correct answer is C. The patient is experiencing an acute infusion reaction, which is likely an IgE-mediated or non-IgE-mediated hypersensitivity reaction. The standard management for a moderate reaction (urticaria, throat tightness without stridor or severe hypotension) is to stop the infusion and administer intravenous antihistamines (like diphenhydramine) and corticosteroids to block the inflammatory cascade. (A) is reserved for anaphylaxis, which is a more severe reaction involving hemodynamic collapse or severe respiratory distress. (B) is incorrect; premedication with acetaminophen is for preventing non-allergic reactions, and restarting the infusion would be contraindicated until the reaction is controlled. (D) addresses nausea and dehydration, not the underlying hypersensitivity mechanism.